TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL …
6 days ago · TEZSPIRE ® (tezepelumab-ekko ... This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of ...
TEZSPIRE met both co-primary endpoints in the Phase III …
6 days ago · TEZSPIRE ® (tezepelumab-ekko) INDICATION TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus. CONTRAINDICATIONS Known hypersensitivity to tezepelumab-ekko or excipients.
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down ...
6 days ago · AstraZeneca and Amgen ’s drug Tezspire reduced nasal congestion and the size of nasal polyps versus placebo in a Phase 3 trial involving people with a form of chronic rhinosinusitis, the ...
AstraZeneca, Amgen Claim Late-Stage Win in Chronic ... - BioSpace
3 days ago · AstraZeneca and Amgen on Friday announced that their subcutaneous antibody Tezspire (tezepelumab) met the primary endpoint in the Phase III WAYPOINT study, demonstrating significant efficacy in patients with chronic rhinosinusitis with nasal polyps.. The partners did not reveal specific data in their news release, only announcing that Tezspire resulted in a “statistically significant and ...
Tezspire Reduces Nasal Congestion and Polyp Size in Chronic …
3 days ago · November 11, 2024. Full results from the trial will be presented at an upcoming medical meeting. Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). Tezepelumab is a human monoclonal antibody ...
Amgen, AZ's Tezspire excels in phase 3 rhinosinusitis trial
6 days ago · AZ reported combined Tezspire sales of $507 million for the two companies in the first half of this year, almost doubling the $257 million from the same period last year. A phase 3 study has shown ...
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE …
May 19, 2024 · TEZSPIRE is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants and other environmental insults.
FDA approves maintenance treatment for severe asthma
Dec 20, 2021 · FDA has approved Tezspire (tezepelumab-ekko) injection as an add-on maintenance treatment used to improve severe asthma symptoms when used with a patient’s current asthma medicine.
FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR ... - Amgen
Dec 17, 2021 · Tezspire is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine. 3 It is the first and only biologic to consistently and significantly reduce asthma exacerbations across Phase 2 and 3 clinical trials, which included a broad ...
Tezspire Meets Co-primary Endpoints in Phase 3 WAYPOINT Trial
3 days ago · November 11, 2024. A Phase III trial, WAYPOINT, has yielded positive results for AstraZeneca and Amgen’s TEZSPIRE (tezepelumab) in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The randomized, double-blind trial demonstrated that TEZSPIRE significantly reduced nasal polyp size and nasal congestion compared to a placebo in adults ...
- Some results have been removed